<DOC>
	<DOCNO>NCT01146977</DOCNO>
	<brief_summary>Evaluation efficacy autologous hematopoietic cell transplantation ( HCT ) core-binding factor ( CBF ) positive acute myeloid leukemia ( AML ) first CR ( CR1 ) .</brief_summary>
	<brief_title>Autologous Hematopoietic Cell Transplantation Core-binding Factor ( CBF ) Acute Myeloid Leukemia ( AML ) First Complete Remission ( CR1 )</brief_title>
	<detailed_description>5.2 AUTOLOGOUS PBSCS HARVESTING 5.2.1 . PBSCs collect recovery phase second cycle HDAC consolidation chemotherapy . 5.2.2 . For mobilization , recombinant human granulocyte- colony-stimulating factor ( G-CSF , Filgrastim ) give subcutaneously dose 10 mcg/kg day 9 2nd HDAC cycle completion harvest . 5.2.3 . PBSCs harvest perform via perm-cath Quinton catheter , insert fluoroscopy-guided start remove finishing harvest . 5.2.4 . Harvest initiate day peripheral absolute neutrophil count reach 0.2 x 109/mm3 . Peripheral blood mononuclear cell collect leukapheresis method 'CS-3000 ' ( Baxter , Deerfield , IL ) compatible machine . Cell collection perform least 2 day duration collection extend target CD34+ cell dose 5 x 106/kg ( term body weight recipient ) collect . 5.2.5 . If adequate number CD34+ cell collect , 3rd HDAC chemotherapy do mobilization/harvest procedure repeat . 5.2.6 . Stem cell harvest patient frozen liquid nitrogen tank future autologous HCT cell infusion . 5.3.PRETRANSPLANT WORKUP FOR AUTOLOGOUS HCT 5.3.1 . Pre-workup check current disease status feasibility autologous HCT perform condition infusion autologous HCT . 5.3.2 . It recommend baseline workup hematologic / non-hematologic status perform least 1 month prior initiation conditioning . Bone marrow aspirate/ biopsy cytogenetics diagnostic lumbar puncture perform immediately initiation conditioning . 5.3.3 . Pretransplant workup test list Appendix IV . 5.4 . CONDITIONING REGIMEN FOR AUTOLOGOUS HCT 5.4.1 . On admission , 5.4.1.1.Menstruating woman give norethindrone ( Norlutate ) 10mg po daily platelet count consistently 100,000 /mcL . 5.4.1.2.Actual body weight ( ABW ) busulfan calculate use follow guideline ; 5.4.1.2.1.If ABW less equal ideal body weight ( IBW ) , use ABW . 5.4.1.2.2.If ABW great IBW ABW within 120 % IBW , use IBW . 5.4.1.2.3.If ABW 120 % great IBW , use IBW+25 % ( ABW-IBW ) . 5.4.1.2.4.IBW ( ideal body weight ) calculate 5.4.1.2.4.1.Male : 50 kg + 2.3kg ( height [ inch ] -60 ) 5.4.1.2.4.2.Female : 45.5kg + 2.3kg ( height [ inch ] -60 ) 5.4.1.2.4.3.1inch=2.54cm 5.4.2 . On day -8 , preparation drug administer patient ; 5.4.2.1.Hydration 0.9 % normal saline start 6PM infuse continuously rate 100mL/hr day -4 . 5.4.2.2.Allopurinol 300mg/day take p.o . day day-8 -2 . 5.4.2.3.Heparin 100 U/kg/day normal saline 500 mL infuse continuously rate 20mL/hr day 20 ( 6pm ) . Heparin discontinue clinically significant bleed aPTT level exceed 1.2 time upper normal limit . 5.4.2.4.Dilantin 15mg/kg ( ABW ) normal saline 300cc infuse continuously rate 200mL/hr 8PM , , 200mg take p.o . twice day day -4 . Dilantin level monitor morning day-7 -6 maintain level within 10 20 mg/L . 5.4.3 . From day-7 , conditioning drug administer patient ; 5.4.3.1.Busulfan 3.2mg/kg/day normal saline 10 time volume busulfan infuse continuously 3 hour interval 24 hour day -7 -5 ( 3 day ) . 5.4.3.2.Etoposide 200mg/m2/day normal saline 1000mL infuse continuously 5 hour twice day interval 12 hour day-3 -2 ( 2 day ) . 5.4.3.3.Antiemetics serotonin antagonist lorazepam allow . 5.5 . AUTOLOGOUS PBSCS INFUSION 5.5.1 . Autologous PBSCs infuse day0 . 5.5.1.1.Premedication include pheniramine maleate ( avil ) 45.5mg i.v. , acetaminophen 600mg p.o. , hydrocortisone 250mg i.v . furosemide 20mg i.v . give 30 minute cell infusion . 5.5.1.2.PBSCs infused via saline infusion set without in-line filter . 5.5.1.3.Vital sign check 4 time 15 minute interval , 4 time 30 minute , 4 time 1 hour . Electrocardiogram monitoring perform start completion PBSCs infusion . 5.5.1.4.Following medication administer simultaneously PBSCs ; 5.5.1.4.1.Lipid-containing total parenteral nutrition fluid 5.5.1.4.2.Conventional liposomal amphotericin 5.6 . SUPPORTIVE CARE 5.6.1 . Recombinant human G-CSF ( rhG-CSF ) 450㎍ 100 mL D5W infuse intravenously 30 minute day 5 till ANC &gt; 3,000/㎕ . 5.6.2 . Ciprofloxacin 500mg give p.o . twice day ( selective bowel decontamination ) day 1 till ANC &gt; 3,000/㎕ . With first fever spike , ciprofloxacin replace broad spectrum antibiotic . 5.6.3 . Micafungin 50mg infused intravenously day day1 till ANC &gt; 3,000/㎕ . 5.6.4 . Acyclovir 250mg/m2 infused twice day day1 till ANC &gt; 3,000/㎕ . 5.6.5 . In case oral mucositis , sodium bicarbonate/saline mouthwash apply four time day resolve . 5.6.6 . Clotrimazole Canesten® powder apply groin , axilla , perianal area twice day day-8 engraftment . 5.6.7 . All cellular blood product must transfuse leukocyte filtration irradiation . 5.6.8 . For woman childbearing potential , adequate consultation ovarian protection seek . For man intend child ( ren ) future , sperm banking recommend perform . 5.7 . EVALUATION DURING TREATMENT 5.7.1 . CBC differential count , ALT/AST , bilirubin BUN/Cr , electrolyte check daily . 5.7.2 . Chemical battery BUN/phosphorus , LDH level magnesium check three time week . 5.7.3 . Coagulation battery fibrinogen/d-dimer check day 0 , 7 , 14 , 21 week thereafter discharge . 5.7.4 . Protein C , antithrombin III , t-PA antigen , PAI-1 antigen check day 0 , 7 , 14 , 21 . 5.7.5 . Urinalysis check week . 5.7.6 . Chest X-ray check week routinely frequently accord patient 's condition . 5.7.7 . Blood galactomannan ( aspergillosis antigen , GM ) assay recommend checked week ANC &gt; 3,000/ accord physician 's decision . 5.8 . POST-HCT FOLLOW-UP INCLUDING MRD MONITORING 5.8.1 . Patients follow physical examination appropriate blood test include CBC least every 3 month 3 year , every 6 month next 2 year , annually thereafter . 5.8.2 . Toxicities related treatment assess report accord NCI CTCAE v3.0 . 5.8.3 . Minimal residual disease ( MRD ) monitor RQ-PCR AML1/ETO CBFβ/MYH11 perform autologous HCT ( bone marrow peripheral blood , 1 month autologous HCT ( bone marrow peripheral blood ) , thereafter , every 3 month ( peripheral blood ) 3 year autologous HCT . 5.8.4 . If RQ-PCR available , RT-PCR and/or FISH use MRD monitoring</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients CBF positive AML CR1 . CBF AML include ( 8 ; 21 ) ( q22 ; q22 ) [ AML1 ( RUNX1 ) /ETO ( CBFα2T1 ) ] , inv ( 16 ) ( q13q22 ) ( CBFβ/MYH11 ) , ( 16 ; 16 ) ( p13 ; q22 ) ( CBFβ/MYH11 ) Using RTPCR , FISH , standard karyotype analysis technique . Patients plan receive second cycle HDAC consolidation chemotherapy . 15 year old old 65 year young Adequate performance status ( Karnofsky score 70 ) . Adequate hepatic renal function ( AST , ALT , bilirubin &lt; 3.0 x upper normal limit , creatinine &lt; 2.0 mg/dL ) . Adequate cardiac function ( left ventricular ejection fraction 40 % heart scan echocardiography ) Signed date informed consent must obtain patient . Presence significant active infection Presence uncontrolled bleed Any coexist major illness organ failure Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible Nursing woman , pregnant woman , woman childbearing potential want adequate contraception Patients diagnosis prior malignancy unless diseasefree least 5 year follow therapy curative intent ( except curatively treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>CBF ( + )</keyword>
</DOC>